In a major change of strategy, the new head of GlaxoSmithKline, Andrew Witty, has told the Guardian he will slash prices on all medicines in the poorest countries, give back profits to be spent on hospitals and clinics and – most ground-breaking of all – share knowledge about potential drugs that are currently protected by patents. Witty says he believes drug companies have an obligation to help the poor get treatment. He challenges other pharmaceutical giants to follow his lead.
Human enhancement and the future of work summarises technological advancements that could dramatically change how people work over the next decade. These technologies, such as cognitive enhancing drugs, bionic limbs and retinal implants, affect various human capacities such as memory, hearing and mobility. The report explores how, although human enhancement technologies might aid society, their use could raise serious ethical, philosophical, regulatory and economic issues that will need further consideration.